11,199 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Bought by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,199 shares of the biopharmaceutical company’s stock, valued at approximately $414,000.

Several other hedge funds have also added to or reduced their stakes in the business. Advisors Asset Management Inc. lifted its stake in Halozyme Therapeutics by 0.6% in the third quarter. Advisors Asset Management Inc. now owns 45,598 shares of the biopharmaceutical company’s stock worth $1,742,000 after purchasing an additional 287 shares during the last quarter. Fifth Third Bancorp lifted its stake in Halozyme Therapeutics by 2.6% in the third quarter. Fifth Third Bancorp now owns 12,262 shares of the biopharmaceutical company’s stock worth $468,000 after purchasing an additional 308 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in Halozyme Therapeutics by 2.2% in the third quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company’s stock worth $619,000 after purchasing an additional 347 shares during the last quarter. Truist Financial Corp lifted its stake in Halozyme Therapeutics by 0.6% in the fourth quarter. Truist Financial Corp now owns 102,622 shares of the biopharmaceutical company’s stock worth $3,793,000 after purchasing an additional 563 shares during the last quarter. Finally, Alliance Wealth Advisors LLC UT lifted its stake in Halozyme Therapeutics by 7.4% in the third quarter. Alliance Wealth Advisors LLC UT now owns 8,389 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 581 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the transaction, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 30,000 shares of company stock worth $1,196,800 in the last quarter. 2.70% of the stock is owned by company insiders.

Halozyme Therapeutics Trading Up 2.4 %

HALO opened at $40.86 on Tuesday. The stock has a market cap of $5.19 billion, a PE ratio of 19.37, a PEG ratio of 0.47 and a beta of 1.26. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. The business has a 50 day moving average of $40.01 and a 200-day moving average of $37.94. Halozyme Therapeutics, Inc. has a 52 week low of $29.85 and a 52 week high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $230.04 million during the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, April 30th. TD Cowen initiated coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price target for the company. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Benchmark reissued a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. Finally, JMP Securities restated a “market outperform” rating and set a $72.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $53.29.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.